The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection

Detalhes bibliográficos
Autor(a) principal: Commodaro, Alessandra Goncalves [UNIFESP]
Data de Publicação: 2012
Outros Autores: Pedregosa, Juliana Figueredo [UNIFESP], Peron, Jean Pierre, Brandao, Wesley, Rizzo, Luiz Vicente, Bueno, Valquiria [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
dARK ID: ark:/48912/001300001391h
Texto Completo: http://dx.doi.org/10.6061/clinics/2012(07)17
http://repositorio.unifesp.br/handle/11600/34416
Resumo: OBJECTIVES: FTY720 modulates CD4(+)T cells by the augmentation of regulatory T cell activity, secretion of suppressive cytokines and suppression of IL-17 secretion by Th17 cells. To further understand the process of graft rejection/acceptance, we evaluated skin allograft survival and associated events after FTY720 treatment.METHODS: F1 mice (C57BL/6xBALB/c) and C57BL/6 mice were used as donors for and recipients of skin transplantation, respectively. the recipients were transplanted and either not treated or treated with FTY720 by gavage for 21 days to evaluate the allograft survival. in another set of experiments, the immunological evaluation was performed five days post-transplantation. the spleens, axillary lymph nodes and skin allografts of the recipient mice were harvested for phenotyping (flow cytometry), gene expression (real-time PCR) and cytokine (Bio-Plex) analysis.RESULTS: the FTY720 treatment significantly increased skin allograft survival, reduced the number of cells in the lymph nodes and decreased the percentage of Tregs at this site in the C57BL/6 recipients. Moreover, the treatment reduced the number of graft-infiltrating cells and the percentage of CD4(+) graft-infiltrating cells. the cytokine analysis (splenocytes) showed decreased levels of IL-10, IL-6 and IL-17 in the FTY720-treated mice. We also observed a decrease in the IL-10, IL-6 and IL-23 mRNA levels, as well as an increase in the IL-27 mRNA levels, in the splenocytes of the treated group. the FTY720-treated mice exhibited increased mRNA levels of IL-10, IL-27 and IL-23 in the skin graft.CONCLUSIONS: Our results demonstrated prolonged but not indefinite skin allograft survival by FTY720 treatment. This finding indicates that the drug did not prevent the imbalance between Tr1 and Th17 cells in the graft that led to rejection.
id UFSP_538ecf3944bb4f61931a839a2bc56966
oai_identifier_str oai:repositorio.unifesp.br/:11600/34416
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejectionTransplantationRejectionToleranceFTY720Foxp3Th17OBJECTIVES: FTY720 modulates CD4(+)T cells by the augmentation of regulatory T cell activity, secretion of suppressive cytokines and suppression of IL-17 secretion by Th17 cells. To further understand the process of graft rejection/acceptance, we evaluated skin allograft survival and associated events after FTY720 treatment.METHODS: F1 mice (C57BL/6xBALB/c) and C57BL/6 mice were used as donors for and recipients of skin transplantation, respectively. the recipients were transplanted and either not treated or treated with FTY720 by gavage for 21 days to evaluate the allograft survival. in another set of experiments, the immunological evaluation was performed five days post-transplantation. the spleens, axillary lymph nodes and skin allografts of the recipient mice were harvested for phenotyping (flow cytometry), gene expression (real-time PCR) and cytokine (Bio-Plex) analysis.RESULTS: the FTY720 treatment significantly increased skin allograft survival, reduced the number of cells in the lymph nodes and decreased the percentage of Tregs at this site in the C57BL/6 recipients. Moreover, the treatment reduced the number of graft-infiltrating cells and the percentage of CD4(+) graft-infiltrating cells. the cytokine analysis (splenocytes) showed decreased levels of IL-10, IL-6 and IL-17 in the FTY720-treated mice. We also observed a decrease in the IL-10, IL-6 and IL-23 mRNA levels, as well as an increase in the IL-27 mRNA levels, in the splenocytes of the treated group. the FTY720-treated mice exhibited increased mRNA levels of IL-10, IL-27 and IL-23 in the skin graft.CONCLUSIONS: Our results demonstrated prolonged but not indefinite skin allograft survival by FTY720 treatment. This finding indicates that the drug did not prevent the imbalance between Tr1 and Th17 cells in the graft that led to rejection.Fed Univ São Paulo UNIFESP, Vis Inst, São Paulo, BrazilHosp Israelita Albert Einstein, São Paulo, BrazilFed Univ São Paulo UNIFESP, Div Nephrol, São Paulo, BrazilUniv São Paulo, Fac Med, Dept Immunol, São Paulo, BrazilFed Univ São Paulo UNIFESP, Div Immunol, São Paulo, BrazilFed Univ São Paulo UNIFESP, Vis Inst, São Paulo, BrazilFed Univ São Paulo UNIFESP, Div Nephrol, São Paulo, BrazilFed Univ São Paulo UNIFESP, Div Immunol, São Paulo, BrazilWeb of ScienceFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Hospital Clinicas, Univ São PauloUniversidade Federal de São Paulo (UNIFESP)Hosp Israelita Albert EinsteinUniversidade de São Paulo (USP)Commodaro, Alessandra Goncalves [UNIFESP]Pedregosa, Juliana Figueredo [UNIFESP]Peron, Jean PierreBrandao, WesleyRizzo, Luiz VicenteBueno, Valquiria [UNIFESP]2016-01-24T14:17:40Z2016-01-24T14:17:40Z2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion805-813application/pdfhttp://dx.doi.org/10.6061/clinics/2012(07)17Clinics. São Paulo: Hospital Clinicas, Univ São Paulo, v. 67, n. 7, p. 805-813, 2012.10.6061/clinics/2012(07)17S1807-59322012000700017.pdf1807-5932S1807-59322012000700017http://repositorio.unifesp.br/handle/11600/34416WOS:000307723100017ark:/48912/001300001391hengClinicsinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-31T23:34:48Zoai:repositorio.unifesp.br/:11600/34416Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:53:05.010957Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
title The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
spellingShingle The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
Commodaro, Alessandra Goncalves [UNIFESP]
Transplantation
Rejection
Tolerance
FTY720
Foxp3
Th17
title_short The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
title_full The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
title_fullStr The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
title_full_unstemmed The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
title_sort The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection
author Commodaro, Alessandra Goncalves [UNIFESP]
author_facet Commodaro, Alessandra Goncalves [UNIFESP]
Pedregosa, Juliana Figueredo [UNIFESP]
Peron, Jean Pierre
Brandao, Wesley
Rizzo, Luiz Vicente
Bueno, Valquiria [UNIFESP]
author_role author
author2 Pedregosa, Juliana Figueredo [UNIFESP]
Peron, Jean Pierre
Brandao, Wesley
Rizzo, Luiz Vicente
Bueno, Valquiria [UNIFESP]
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
Hosp Israelita Albert Einstein
Universidade de São Paulo (USP)
dc.contributor.author.fl_str_mv Commodaro, Alessandra Goncalves [UNIFESP]
Pedregosa, Juliana Figueredo [UNIFESP]
Peron, Jean Pierre
Brandao, Wesley
Rizzo, Luiz Vicente
Bueno, Valquiria [UNIFESP]
dc.subject.por.fl_str_mv Transplantation
Rejection
Tolerance
FTY720
Foxp3
Th17
topic Transplantation
Rejection
Tolerance
FTY720
Foxp3
Th17
description OBJECTIVES: FTY720 modulates CD4(+)T cells by the augmentation of regulatory T cell activity, secretion of suppressive cytokines and suppression of IL-17 secretion by Th17 cells. To further understand the process of graft rejection/acceptance, we evaluated skin allograft survival and associated events after FTY720 treatment.METHODS: F1 mice (C57BL/6xBALB/c) and C57BL/6 mice were used as donors for and recipients of skin transplantation, respectively. the recipients were transplanted and either not treated or treated with FTY720 by gavage for 21 days to evaluate the allograft survival. in another set of experiments, the immunological evaluation was performed five days post-transplantation. the spleens, axillary lymph nodes and skin allografts of the recipient mice were harvested for phenotyping (flow cytometry), gene expression (real-time PCR) and cytokine (Bio-Plex) analysis.RESULTS: the FTY720 treatment significantly increased skin allograft survival, reduced the number of cells in the lymph nodes and decreased the percentage of Tregs at this site in the C57BL/6 recipients. Moreover, the treatment reduced the number of graft-infiltrating cells and the percentage of CD4(+) graft-infiltrating cells. the cytokine analysis (splenocytes) showed decreased levels of IL-10, IL-6 and IL-17 in the FTY720-treated mice. We also observed a decrease in the IL-10, IL-6 and IL-23 mRNA levels, as well as an increase in the IL-27 mRNA levels, in the splenocytes of the treated group. the FTY720-treated mice exhibited increased mRNA levels of IL-10, IL-27 and IL-23 in the skin graft.CONCLUSIONS: Our results demonstrated prolonged but not indefinite skin allograft survival by FTY720 treatment. This finding indicates that the drug did not prevent the imbalance between Tr1 and Th17 cells in the graft that led to rejection.
publishDate 2012
dc.date.none.fl_str_mv 2012-01-01
2016-01-24T14:17:40Z
2016-01-24T14:17:40Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.6061/clinics/2012(07)17
Clinics. São Paulo: Hospital Clinicas, Univ São Paulo, v. 67, n. 7, p. 805-813, 2012.
10.6061/clinics/2012(07)17
S1807-59322012000700017.pdf
1807-5932
S1807-59322012000700017
http://repositorio.unifesp.br/handle/11600/34416
WOS:000307723100017
dc.identifier.dark.fl_str_mv ark:/48912/001300001391h
url http://dx.doi.org/10.6061/clinics/2012(07)17
http://repositorio.unifesp.br/handle/11600/34416
identifier_str_mv Clinics. São Paulo: Hospital Clinicas, Univ São Paulo, v. 67, n. 7, p. 805-813, 2012.
10.6061/clinics/2012(07)17
S1807-59322012000700017.pdf
1807-5932
S1807-59322012000700017
WOS:000307723100017
ark:/48912/001300001391h
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Clinics
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 805-813
application/pdf
dc.publisher.none.fl_str_mv Hospital Clinicas, Univ São Paulo
publisher.none.fl_str_mv Hospital Clinicas, Univ São Paulo
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1818602561992654848